PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
Treatment with PDC*lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab PDC*line Pharma, a clinical stage biotech